• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.13% Nasdaq Up0.70%

    Venaxis, Inc. (APPY)

    -NasdaqCM
    1.71 Up 0.01(0.59%) Dec 26, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Venaxis, Inc.
    1585 South Perry Street
    Castle Rock, CO 80104
    United States - Map
    Phone: 303-794-2000
    Fax: 303-798-8332
    Website: http://www.venaxis.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Diagnostic Substances
    Full Time Employees:20

    Business Summary 

    Venaxis, Inc. develops and commercializes products for unmet diagnostic and therapeutic needs. The company’s research and development activities primarily focus on a human acute appendicitis blood-based test. Its lead product candidate includes APPY1, a novel blood-based diagnostic test designed to aid in the evaluation of patients for acute appendicitis. Venaxis, Inc., through its license agreement with Washington University in St. Louis, develops, markets, sells, distributes, imports, and exports luteinizing hormone and/or follicle-stimulating hormone products for bovine, equine, and swine animals. The company was formerly known as AspenBio Pharma, Inc. and changed its name to Venaxis, Inc. in December 2012. Venaxis, Inc. was founded in 2000 and is based in Castle Rock, Colorado.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Venaxis, Inc.

    Key Executives 
     PayExercised
    Mr. Stephen T. Lundy , 53
    Chief Exec. Officer, Pres and Director
    401.00K0.00
    Mr. Jeffrey G. McGonegal , 63
    Chief Financial Officer, Principal Accounting Officer and Corp. Sec.
    284.00K0.00
    Mr. Donald R. Hurd , 62
    Chief Commercial Officer and Sr. VP
    275.00K0.00
    Dr. Mary H. Nunnally Ph.D.,
    VP of Quality
    N/AN/A
    Dr. Lyndal Hesterberg Ph.D.,
    Consultant
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders